US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Alpha Tau Medical Warrant

0.2738

0.0000

Volume:30.00

Turnover:8.62

Market Cap:- -

PE:- -

High:0.2738

Open:0.2738

Low:0.2738

Close:0.2738

52wk High:0.5000

52wk Low:0.1300

Shares:- -

Float Shares:- -

Volume Ratio:0.01

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Alpha Tau Announces Appointment of Nadav Kidron to Its Board of Directors

THOMSON REUTERS

Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals

BRIEF-Alpha Tau Receives FDA Approval To Initiate A Trial For Patients With Recurrent Glioblastoma

Alpha Tau Receives FDA Approval to Initiate a Trial for Patients With Recurrent Glioblastoma

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/DRTSW"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"DRTSW","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DRTSW\",,,,,undefined,":{"symbol":"DRTSW","market":"US","secType":"STK","nameCN":"Alpha Tau Medical Warrant","latestPrice":0.2738,"timestamp":1755806400000,"preClose":0.2738,"halted":0,"volume":30,"delay":0,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Post-Mkt","change":0,"latestTime":"08-21 17:37:08 EDT","open":0.2738,"high":0.2738,"low":0.2738,"amount":8.619,"amplitude":0,"askPrice":0.3907,"askSize":100,"bidPrice":0.2013,"bidSize":100,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1755820800000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":0.2738,"volumeRatio":0.00561},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DRTSW\",,,,,undefined,":{"symbol":"DRTSW","floatShares":0,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.00561,"shares":0,"dividePrice":0,"high":0.2738,"amplitude":0,"preClose":0.2738,"low":0.2738,"week52Low":0.13,"pbRate":"--","week52High":0.5,"institutionHeld":0,"latestPrice":0.2738,"eps":0,"divideRate":0,"volume":30,"delay":0,"ttmEps":0,"open":0.2738,"prevYearClose":0.21,"prevWeekClose":0.2726,"prevMonthClose":0.23,"prevQuarterClose":0.2401,"fiveDayClose":0.2726,"twentyDayClose":0.2538,"sixtyDayClose":0.25},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DRTSW\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DRTSW\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"DRTSW\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"DRTSW\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2535789352","title":"Alpha Tau Announces Appointment of Nadav Kidron to Its Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2535789352","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535789352?lang=en_us&edition=fundamental","pubTime":"2025-05-13 04:01","pubTimestamp":1747080061,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250512:nTUA8MJWYM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","DRTSW","DRTS"],"gpt_icon":0},{"id":"2530883862","title":"Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2530883862","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530883862?lang=en_us&edition=fundamental","pubTime":"2025-04-28 21:00","pubTimestamp":1745845200,"startTime":"0","endTime":"0","summary":"Investment comes at a pivotal moment for Alpha Tau, which is experiencing remarkable growth on multiple fronts, with four active U.S. trial approvals, expansion into multiple internal organ applications, scaling up of manufacturing capabilities, and commercial preparations underway. The total gross proceeds of the offering were approximately $36.9 million, before deducting estimated offering expenses payable by Alpha Tau. Alpha Tau intends to use the net proceeds from the offering for general corporate purposes, including research and development-related purposes in connection with its product candidates, for expansion of its manufacturing capabilities and for potential commercialization of its product candidates.A registration statement on Form F-3 relating to the securities to be sold in the registered direct offering has been filed with the U.S. Securities and Exchange Commission  and was declared effective on April 13, 2023. This registered direct offering was made only by means of","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alpha-tau-announces-closing-36-130000537.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["DRTS","BK4082","ORMP","DRTSW","BK4007"],"gpt_icon":0},{"id":"2524495730","title":"BRIEF-Alpha Tau Receives FDA Approval To Initiate A Trial For Patients With Recurrent Glioblastoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2524495730","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524495730?lang=en_us&edition=fundamental","pubTime":"2025-04-02 21:07","pubTimestamp":1743599259,"startTime":"0","endTime":"0","summary":"BRIEF-Alpha Tau Receives FDA Approval To Initiate A Trial For Patients With Recurrent GlioblastomaApril 2 (Reuters) - Alpha Tau Medical Ltd DRTS.O:ALPHA TAU RECEIVES FDA APPROVAL TO INITIATE A TRIAL F","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250402:nTUA3Q0DSD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","DRTS","DRTSW"],"gpt_icon":0},{"id":"2524498553","title":"Alpha Tau Receives FDA Approval to Initiate a Trial for Patients With Recurrent Glioblastoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2524498553","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524498553?lang=en_us&edition=fundamental","pubTime":"2025-04-02 20:30","pubTimestamp":1743597000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250402:nTUA3Q0DSD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","DRTS","DRTSW"],"gpt_icon":0}],"pageSize":4,"totalPage":4,"pageCount":1,"totalSize":13,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/DRTSW\",params:#limit:6,delay:false,,,undefined,":[]}}